CID: Immunogenicity and safety of quadrivalent human papillomavirus vaccine in HIV-1 infected women

Persistent infection with carcinogenic human papillomavirus (HPV) can cause anal and cervical intraepithelial neoplasia and cancer
.

Compared with women who are not infected with HIV, women infected with human immunodeficiency virus (HIV) are disproportionately affected by HPV-related anal diseases

Persistent infection with carcinogenic human papillomavirus (HPV) can cause anal and cervical intraepithelial neoplasia and cancer

Method
.

Detect the safety and serum status of HPV types 6, 11, 16, and 18

Result
.

The median age of the patients was 36 years, 11% were white, 56% were black, and 31% were Hispanic

Table 1 Human papillomavirus antibody concentration of a certain seronegative type participant at the 28th week at baseline

Table 1 Human papillomavirus antibody concentration of a certain seronegative type participant at the 28th week at baseline

Table 2 Human papillomavirus antibody concentration of participants with a certain seropositive type at baseline at 28 weeks

Table 2 Human papillomavirus antibody concentration of participants with a certain seropositive type at baseline at 28 weeks

Conclusion: The tetravalent HPV vaccine for types 6, 11, 16 and 18 is safe and immunogenic in HIV-infected women aged 13-45
.

The seroconversion rate of women with HIV RNA load >10 000 copies/mL and/or CD4 count <200 cells/μL is lower

The tetravalent HPV vaccines against types 6, 11, 16 and 18 are safe and immunogenic in HIV-infected women aged 13-45

Kojic EM, Kang M,Cespedes MS,et al,Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women.

Cespedes MS,et al,Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women.
Leave a message here